Normal immunoglobulins

Table 10. Properties of Normal Immunoglobulin and Intravenous Immunoglobulin...

Normal Immunoglobulin Levels in Burkitt s Lymphoma Normal IgM AND Normal IgG (mg/ml) ... 

Normal immunoglobulin Human Specificities against variety of infectious and other biological agents prevalent in general population... 

Normal immunoglobulins (often termed immune globulins in the USA) represent antibody preparations purified from the plasma, serum or placentas of normal, healthy donors. Blood obtained from such individuals will contain a wide range of antibody specificities. The range of specificities were produced over many years, as the individual s immune system came into contact with various antigens, either naturally (infections) or artificially (by vaccination). 

Normal immunoglobulin preparations are purified from pooled material obtained from 1000 or more donors. They will generally contain antibodies against diphtheria, measles, poliomyelitis, hepatitis A, rubella and varicella. Normal immunoglobulin may, therefore, be used to provide passive immunization against these diseases. 

Normal immunoglobulins are prepared from material from blood donors and contain several antibodies against infectious diseases prevalent in the general... 

Histaglobulin is a lyophilised preparation of histamine (as histamine dihydrochloride) coupled with human normal immunoglobulin. 

Human normal immunoglobulins hormone also [760] HPLC [767] somatropin for injection [918] ... 

Human normal immunoglobulin (HNIG) is prepared from screened, human plasma. The antibody fraction is extensively purified and contains immunoglobulins in glycine. Some products may contain sorbitol (refer to product information). HNIG is also used to treat possible infections as it contains antibodies to infectious pathogens against which the donors have been immunised. 

Passive immunity can be obtained by i.m. injection of globulin containing antibody to the virus normal immunoglobulin prepared from pooled plasma from known immune donors) which confers temporary protection for travellers visiting areas where the virus is endemic. Active immunisation with Hepatitis A vaccine is now preferable protective antibody takes about two weeks to develop. 

Maltose is used in oral and parenteral pharmaceutical formulations and is generally regarded as an essentially nontoxic and nonirritant material. However, there has been a single report of a liver transplantation patient with renal failure who developed hyponatremia following intravenous infusion of normal immunoglobulin in 10% maltose. The effect, which recurred on each of four successive infusions, resembled that of hyperglycemia and was thought to be due to accumulation of maltose and other osmotically active metabolites in the extracellular fluid. ... 

Noristerat norethisterone. norleusaetide pentacosactride. normal immunoglobulin globulin,immune, nor MDP almurtide. 

None detected <1 0 Usually reduction of normal immunoglobulins... 

How does this suppression of normal immunoglobulin synthesis occur Simple displacement of the normal plasma cells by neoplastic cells seems unlikely, because in the marrow this would also result in leukoerythro-blastic anemia this in fact is found in fewer than 5% of these patients. Marrow occupation would also depress IgG first (Section 4.3), whereas this is usually the last to fall. Furthermore, IgA is largely derived from the gut, which is rarely directly involved by tumor. It has also been suggested that the neoplastic cells misappropriate available amino acids at the expense of normal plasma cells. Immunoglobulin deficiency is, however, unusual with most other types of neoplasia, and even among the... 

Nl. Nahmias, A. J., Griffith, D., Salsbury, C., and Yoshida, K., Thymic aplasia with lymphopenia, plasma cells, and normal immunoglobulins. Relation to measles virus infection. J. Amer. Med. Ass. 201, 729-734 (1967). 

Bouvet JP, Pires R, Quan CP Protein Fv (Fv fragment binding protein) a mucosal human superantigen reacting with normal immunoglobulins in Zouali M (ed) Human B Cell Superantigens. Austin, RG Landes Company, 1996, pp 179-188. 

---